Role of endothelin-1 and thromboxane A2 in the pulmonary hypertension induced by heparin-protamine interaction in anesthetized dogs.
This study aimed to study the role of thromboxane A2 (TXA2) and endothelin-1 (ET-1) in the pulmonary hypertension induced by interaction of heparin-protamine in anesthetized dogs. The effect of inhaled nitric oxide (NO) was also investigated in this model. Dogs were anesthetized and instrumented for acquisition of mean arterial blood pressure, mean arterial pulmonary pressure (MPAP), and pulmonary pressure gradient (PPG). Cardiac index (CI), heart rate, and index of systemic vascular resistance were also obtained. Intravenous administration of heparin (500 IU/kg) 3 minutes before protamine (10 mg/kg) caused marked pulmonary hypertension, as evaluated by the increase in MPAP and PPG. This was accompanied by systemic hypotension, CI decrease, and tachycardia. Indomethacin (10 mg/kg), dazoxiben (10 mg/kg), or tezosentan (10-mg/kg bolus plus 10-mg/kg/h infusion) significantly reduced the increase in MPAP and PPG, but had no effect on the systemic hypotension. Similar results were obtained with inhaled NO (3 ppm). Plasma TXB2 levels were markedly elevated during the pulmonary hypertension, and this was abolished in indomethacin-treated dogs. Our study shows that interaction of heparin-protamine in anesthetized dogs lead to TXA2- and ET-1-mediated pulmonary hypertension. Drugs that interfere with the synthesis of these mediators as well as inhaled NO may be of beneficial value to control this disorder.
Freitas
Cristiane F
CF
Department of Pharmacology, Faculty of Medical Sciences, UNICAMP, Campinas, Brazil.
Faro
Renato
R
Dragosavac
Desanka
D
Clozel
Martine
M
De Nucci
Gilberto
G
Antunes
Edson
E
D000280:Administration, Inhalation; D000818:Animals; D004285:Dogs; D019332:Endothelin-1 / Q000096:biosynthesis / Q000502:physiology*; D005260:Female; D006494:Heparin Antagonists / Q000009:adverse effects; D006976:Hypertension, Pulmonary / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage / Q000627:therapeutic use*; D011479:Protamines / Q000009:adverse effects; D013928:Thromboxane A2 / Q000096:biosynthesis / Q000502:physiology*; D013929:Thromboxane B2 / Q000097:blood
D019332:Endothelin-1; D006494:Heparin Antagonists; D011479:Protamines; D009569:Nitric Oxide; D013929:Thromboxane B2; D013928:Thromboxane A2